Drugs / GLS-5310
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05182567 | May 2022 → Jan 2023 | COVID-19 | GeneOne Life Science, Inc. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04673149 | Dec 2020 → Mar 2021 | COVID-19 | GeneOne Life Science, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLS-5310 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673149 ↗ |
| Modality | Vaccine | “GLS-5310 DNA plasmid vaccine” NCT04673149 ↗ |
| Route | Other | “will be intradermally administered” NCT04673149 ↗ |